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Abstract
Background: Recent developments of high throughput sequencing technologies allow the characterization of the
microbial communities inhabiting our world. Various metagenomic studies have suggested using microbial taxa as
potential biomarkers for certain diseases. In practice, the number of available samples varies from experiment to
experiment. Therefore, a robust biomarker detection algorithm is needed to provide a set of potential markers
irrespective of the number of available samples. Consistent performance is essential to derive solid biological
conclusions and to transfer these findings into clinical applications. Surprisingly, the consistency of a metagenomic
biomarker detection algorithm with respect to the variation in the experiment size has not been addressed by the
current state-of-art algorithms.
Results: We propose a consistency-classification framework that enables the assessment of consistency and
classification performance of a biomarker discovery algorithm. This evaluation protocol is based on random
resampling to mimic the variation in the experiment size. Moreover, we model the metagenomic data matrix as a
superposition of two matrices. The first matrix is a low-rank matrix that models the abundance levels of the irrelevant
bacteria. The second matrix is a sparse matrix that captures the abundance levels of the bacteria that are differentially
abundant between different phenotypes. Then, we propose a novel Robust Principal Component Analysis (RPCA)
based biomarker discovery algorithm to recover the sparse matrix. RPCA belongs to the class of multivariate feature
selection methods which treat the features collectively rather than individually. This provides the proposed algorithm
with an inherent ability to handle the complex microbial interactions. Comprehensive comparisons of RPCA with the
state-of-the-art algorithms on two realistic datasets are conducted. Results show that RPCA consistently outperforms
the other algorithms in terms of classification accuracy and reproducibility performance.
Conclusions: The RPCA-based biomarker detection algorithm provides a high reproducibility performance
irrespective of the complexity of the dataset or the number of selected biomarkers. Also, RPCA selects biomarkers with
quite high discriminative accuracy. Thus, RPCA is a consistent and accurate tool for selecting taxanomical biomarkers
for different microbial populations.
Reviewers: This article was reviewed by Masanori Arita and Zoltan Gaspari.
Keywords: Biomarker detection, Metagenomics, Robust PCA
Background
With trillions of microbes inhabiting the human body,
bacteria play an essential role in defining the health and
disease states of the host. In general, these microbial
inhabitants outnumber the human’s cells and comprise
about 150 times more genes than the human genome [1].
*Correspondence: eserpedin@tamu.edu
1Bioinformatics and Genomic Signal Processing Lab, ECEN Dept., Texas A&M
University, 77843-3128 College Station, TX, USA
Full list of author information is available at the end of the article
Some studies have reported that the microbes outnumber
the human’s cells by a ratio of 10:1 [2], while others limits
this ratio to 1.3:1 [3]. However, investigating the bacte-
rial communities has been limited in the past because
more than 90% of microbes are unknown and uncultivable
[4, 5]. Recent advancements in sequencing technologies
have overcome these limitations and provided researchers
with the taxonomic composition and functional capacity
of microbial colonies [6, 7].
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Variousmetagenomic studies have associated the imbal-
ance in bacterial communities with certain diseases rang-
ing from obesity [8–10], diabetes [11], inflammatory
bowel disease (IBD) [12] to cancer [13, 14]. This suggests
using microbes as potential biomarkers for host’s health
and disease states.Moreover, the continuous development
of inexpensive, high throughput sequencing technologies
has prompted the widespread use of microbial biomarker
discovery studies.
Biomarker detection presents itself as a major means of
translating metagenomic data into clinical practice [15].
Identifying potential biomarkers is essential in under-
standing disease evolution and designing antibiotic and/or
probiotic therapies. Microbial biomarker discovery aims
to identify the specific operational taxonomic units
(OTUs), whose relative abundances differ between differ-
ent phenotypes. Mathematically, identifying biomarkers is
cast as the problem of finding the most informative vari-
ables (or features) that discriminate two or more groups of
samples (i.e., healthy versus diseased, or different disease
stages).
Identifying the most discriminating features in metage-
nomic datasets is a challenging task for several rea-
sons. First, the number of features representing potential
biomarkers is large, a challenge that is commonly referred
to as ‘the curse of dimensionality’. The challenges asso-
ciated with analyzing the high dimensional metagenomic
data set is compounded by the small number of avail-
able samples. This high-dimension small-sample chal-
lenge raises serious analytical challenges [16, 17]. Second,
many microbial populations exhibit a high inter-subject
variability. For example, [9] shows that the gut bacterial
ecosystems of twins differ significantly. This inter-subject
variability adds more confounding factors that complicate
the analysis and interpretation of the results. Third, the
microbial communities exhibit a high dynamics due to the
complex relationships between its members [18–20] and
the direct interaction with the host [21]. Fourth, metage-
nomic data are subject to their own artifacts including
sequencing errors and chimeric reads [22, 23].
Ensuring the reproducibility of the results drawn from
biological data is crucial for clinical applications and to
prevent incorrect biological conclusions. For example,
around 70 gene markers for breast cancer were identi-
fied by each of the two large-scale gene expression studies
[24, 25]. However, only three genes were found to be com-
mon between the two sets of identified biomarkers [26].
As an additional example, in the work of Ressom et al. [27],
only seven features have been consistently appeared in the
best 7–8 detected biomarkers determined using a combi-
nation of particle swarm optimization (PSO) and support
vector machine (SVM) as well as in the 128 detected
biomarkers detected via a filtering approach based on t-
test. These facts point out a serious inconsistency problem
that prevents many biomarker detection algorithms from
identifying the correct biomarkers involved in the biolog-
ical process under study. Therefore, measuring the consis-
tency of biomarkers discovery algorithms is an important
metric in the assessment and design of such algorithms.
The biomarker discovery problem can be tackled in
two general frameworks: (i) the statistical framework,
and (ii) the machine learning framework. In general, the
statistical methods resume to applying a statistical test
to compute a p-value for each feature and selecting the
features with p-values lower than a predefined thresh-
old as biomarkers. The associated multiple hypothesis
problems are typically handled by replacing the p-values
with false discovery rates (FDRs). Currently, Metastats
[28] and LEFSe [15] are the only two available meth-
ods that explicitly apply statistical assessment approach of
metagenomic differences for metagenomic biomarker dis-
covery. Metastats employs a nonparametric t-test using
permutations for the non-sparse features and exact fea-
ture tests for the sparse features. LEFSe couples the sta-
tistical analysis with the effect size estimation to achieve
a robust biomarker discovery. For statistical assessment,
LEFSe employs the non-parametric Kruskal-Wallis and
Wilcoxon-Mann–Whitney tests for class and subclass
comparisons, respectively.
From the machine learning perspective, the biomarker
detection task is cast as a feature selection problem. The
most commonly used feature selection methods are the
filtering approaches. In filtering methods, each feature
(i.e., OTU) is scored individually and independently of
the other features. Then, the OTUs with high scores are
selected as potential biomarkers. The score for each fea-
ture is calculated according to the relevance between the
abundance levels of the OTU in the samples and the class
labels of the samples. The individual and independent
ranking renders the filtering methods to be computation-
ally simple and fast. On the other hand, individual rank-
ing ignores the dependencies between variables. In other
words, individual and independent ranking in filtering
methods neglects the fact that a feature may be irrelevant
individually but strongly relevant if it is combined with
other features.
To overcome the individual scoring problem, the feature
transformation approaches attempt to adopt more infor-
mative features where each new feature is a function of all
the initial features. Hence, the dependencies between fea-
tures are implicitly expressed in the constructed features.
Depending on whether the class labels are considered in
the transform function, the feature transformation meth-
ods are broadly divided into supervised and unsupervised
methods. The most prominent unsupervised method is
the principal component analysis (PCA). PCA employs
an orthogonal linear transformation that seeks preserv-
ing the variance of the data. In the category of supervised
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methods, partial least squares (PLS) and linear discrimi-
nant analysis (LDA) are the widely used methods. These
methods have been extensively used for the analysis of
biological data.
Recently, the authors in [29] have proposed an algorithm
to recover the low-rank and sparse matrices from their
superposition. This matrix recovery problem is referred
to as robust PCA (RPCA). It can be easily described by
means of the following matrix decomposition. Assume
matrix D is decomposed as follows:
D = L + S, (1)
where L is a low-rankmatrix and S is a sparse perturbation
matrix. The entries of L are of arbitrary magnitude and
its low-dimensional column and row spaces are unknown.
Similarly, the number and location of the nonzero entries
of S are unknown and they can assume arbitrary large
magnitudes. The key feature of RPCA is that it can recover
both L and S by solving a convex optimization problem,
referred to as Principal Component Pursuit.
Surprisingly, the two state-of-the-art biomarker detec-
tion algorithms (i.e., MetaStats and LEFSe) have not
included the stability performance in the assessment of
the quality of the detected biomarkers. Therefore, we pro-
pose a protocol for evaluating a biomarker detection algo-
rithm in terms of both (i) the consistency of the detected
biomarkers and (ii) the classification performance. This
proposed protocol was motivated by the model selection
approach developed in [30] to find the optimal feature
selection-classifier combination for a given dataset. More-
over, we propose a novel method to identify microbial
biomarkers based on RPCA. The essence of our pro-
posed method is to model the differentially and non-
differentially abundant OTUs as a sparse and low-rank
matrix, respectively. The reasoning behind this model lies
in the fact that the majority of the microbes are irrelevant
to the biological process at hand. Therefore, these irrele-
vant OTUs are supposed to have abundance levels that do
not vary between two different phenotypes (i.e., healthy
and diseased). Hence, it is natural to consider their abun-
dance level matrix as a low-rank matrix (denoted by L).
On the other hand, the abundance levels of the few rele-
vant OTUs exhibit significant variations between the two
phenotypes. This can be represented by a sparse matrix
(denoted by S). The RPCA is employed to decompose
the OTUs abundances matrix into the superposition of L
and S. Then, the bacterial biomarkers are identified based
on the recovered matrix S. Although the RPCA exhib-
ited success in several applications such as surveillance
video and face recognition [29], and identifying differen-
tially expressed genes from gene expression data [31], it
has not been applied to identify potential bacterial mark-
ers from metagenomic data. Moreover, the consistency
performance of RPCA has not been addressed in [31].
Methods
Data description
Unless stated otherwise, the 16S rRNA gene sequenc-
ing reads were assigned to operational taxonomic units
(OTUs) using the naive Bayesian classifier employed by
the Ribosomal Database Project (RDP) [32]. Reads with
confidence below 80% were assigned to be uncertain. For
all the datasets described below, the per-sample normal-
ized read counts were organized in a matrix called the
taxonomic relative abundances matrix. This matrix is the
final input for the RPCA algorithm. As RPCA belongs to
the unsupervised family of machine learning algorithms,
the labels of the data are not required.
Canine inflammatory bowel disease (IBD) dataset
Naturally passed fecal samples were obtained from 89
healthy dogs and 79 dogs with chronic signs of gastroin-
testinal disease and confirmed inflammatory changes on
histopathology. All dogs participated in different clinical
studies and leftover fecal samples were utilized for this
study.
Dogs with clinical signs of chronic GI disease (i.e., vom-
iting, diarrhea, anorexia, weight loss, etc.) were diagnosed
with idiopathic IBD based on the World Small Animal
Veterinary Association (WSAVA) criteria: (i) chronic (i.e.,
≥ 3 weeks) GI signs; (ii) histopathologic evidence of
mucosal inflammation; (iii) inability to document other
causes of GI inflammation; (iv) inadequate response to
dietary, antibiotic, and anthelmintic therapies, and (v)
clinical response to anti-inflammatory or immunosup-
pressive agents. Histological samples were obtained endo-
scopically. Clinical status of each dog was evaluated using
a published clinical canine IBD activity index (CIBDAI).
Within the IBD dogs, 47 dogs had histological confirmed
inflammation in the small intestine, 24 dogs had histo-
logical changes in both small intestine and colon, and 7
dogs had only histological changes reported in the colon.
Histological changes were predominantly of lymphoplas-
macytic infiltrates, with a subset of dogs also show-
ing eosinophilic and/or neutrophilic components. Data
can be downloaded from this link: https://qiita.ucsd.edu/
study/description/833.
Mousemodel of ulcerative colitis (UC) dataset
This dataset represents the fecal microbiota ofmicemodel
with ulcerative colitis and control mice. In particular,
the microbiota of 20 T-bet−/− x Rag2−/− (UC) and 10
Rag2−/− (control) mice was characterized using 16S data
from fecal samples. The data is publicly available in the
supplementary material of [15].
Consistency-classification evaluation protocol
The proposed protocol is based on measuring the con-
sistency and the classification performance over different
Alshawaqfeh et al. Biology Direct  (2017) 12:4 Page 4 of 16
variations of the original dataset. In particular, an empiri-
cal estimation of the consistency has been designed based
on the idea that a stable biomarker detection algorithm
should yield similar results under small variations of the
dataset. This complies with the expectations of biolo-
gists that modifying the original dataset by adding or
removing a few samples should not lead to a significant
change on the identified biomarkers by an algorithm. Con-
sequently, the procedure for estimating the consistency
assumes the following steps. The first step is to repeat-
edly, for K times, subsample the original dataset D ∈
p×N+ into two subsets: Dtraink ∈ p×rN+ and Dtestk ∈
p×(N−rN)+ , where k stands for the iteration number. The
second step is to apply the biomarker detection algorithm
on the
{Dtraink
}K
k=1 subsets to findK sets of potential mark-
ers. The third step is to measure the pairwise similarity
between the K(K−1)2 pairs of the biomarker sets using a
similarity or stability index. Then, the overall consistency
(Cavg) of the algorithm is defined as the average of all
pairwise similarities. Mathematically,
Cavg =
2
∑K
i=1
∑K
j=i+1 SI(Fi,Fj)
K(K − 1) , (2)
where Fi denotes the output of the biomarker detec-
tion method over the i′th subsample. SI(Fi,Fj) represents
the similarity between two marker sets measured by the
stability (i.e., similarity) index SI.
Similarly, we use the same subsamples to evaluate the
classification performance. Particularly, the data corre-
sponding to the selected markers in each generated train-
ing and testing subsets are extracted and are denoted by
Dtraink (Fk) andDtestk (Fk), respectively. TheDtraink (Fk) sub-
set is utilized to train the classifier, while the Dtestk (Fk)
serves as an independent set for testing the classi-
fier. Repeating the evaluation for K times reduces the
risk of over-optimistic results of the conventional cross-
validation on small-sample studies [33]. This consistency-
classification evaluation protocol is summarized in Fig 1.
Consistency performance
Several measures have been proposed to measure the sim-
ilarity between two sets (i.e., the output of a biomarker
detection algorithm over two subsamples). In this work,
we adopt the Kuncheva index (KI) [34] as a measure of
similarity. KI is defined as
KI(Fi,Fj) = p.|Fi ∩ Fj| − T
2
T .(p − T) =
|Fi ∩ Fj| − (T2/p)
T − (T2/p) ,
(3)
Fig. 1 Consistency-classification evaluation protocol
where T = |Fi| = |Fj|. The Kuncheva index ranges
from −1 to 1. The larger the value, the more common
biomarkers among the two sets Fi and Fj. Negative val-
ues indicate that the shared biomarkers are mostly due
to chance. Negative values can be obtained due to the
correction term (T2/p) that aims to compensate for pos-
sible bias due to the randomly selected biomarkers and are
common among the two marker lists.
Classification performance
The classification performance is measured in terms of
sensitivity, specificity and accuracy. The accuracy repre-
sents the portion of the correctly classified instances in
both classes (ex., healthy and diseased). In case of imbal-
anced class distribution, accuracy becomes misleading
since it is dominated by the majority class. This is par-
ticularly true when the prediction of the minority group
is critical. Therefore, to complete the picture about the
classification performance, class-specific measures such
as sensitivity and specificity are also important. Sensitiv-
ity and specificity are defined as the portion of correctly
predicted instances in the positive (i.e., diseased) and neg-
ative (i.e., healthy) classes, respectively. Let TN and TP
denote the number of correctly identified negative and
positive samples, respectively. Also, let FN and FP repre-
sent the number of false-classified samples in the negative
and positive classes, respectively. Then, the accuracy, sen-
sitivity and specificity are defined as follows:
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Accuracy = TP + TNTP + FN + TN + FP , (4)
Sensitivity = TPTP + FN , (5)
Specificity = TNTN + FP . (6)
Robust principal component analysis
RPCA is a matrix recovery problem which aims to recover
the low-rank matrix L and the sparse matrix S from their
superposition D. The authors in [29, 35] have shown that
under broad assumptions, it is possible to exactly recover
both components (i.e., low rank and sparse matrices)
by solving a convex optimization problem called Princi-
pal Component Pursuit (PCP). PCP aims to minimize a
weighted sum of the nuclear norm of the low-rank matrix
and of the l1 norm of the sparse matrix. Mathematically,
PCP is expressed as
minimize ‖L‖∗ + λ‖S‖1
subject to D = L + S, (7)
where λ is a positive regularization parameter that con-
trols the sparseness and smoothness of S and L, respec-
tively. ‖L‖∗ denotes the nuclear norm of the matrix L and
it is equal to the sum of the singular values of the matrix.
‖S‖1 represents the l1 norm of the matrix and it is equal
to the sum of the absolute values of all the matrix entries.
Various methods have been proposed for solving the
PCP problem such as the iterative thresholding approach
[36] and the accelerated proximal gradient approach [37].
In this paper, we adopt the augmented Lagrangemultiplier
(ALM) algorithm to solve (7). In general, ALM algorithms
solve constrained optimization problems by converting
them into unconstrained problems with a new objec-
tive called the augmented Lagrangian. The augmented
Lagrangian for the PCP problem is given by
l(L, S,Y) = ‖L‖∗ + λ‖S‖1+
〈Y,D − L − S〉 + μ2 ‖D − L − S‖2F ,
(8)
where Y represents the Lagrange multiplier matrix, and μ
stands for the single regularization parameter associated
with the ALM formulation. Thus, the ALM formulation of
the PCP problem is given by
minimize l(L, S,Y) = ‖L‖∗ + λ‖S‖1+
〈Y,D − L − S〉 + μ2 ‖D − L − S‖2F .
(9)
A standard approach to solve (9) is of iterative-based
nature. Each iteration k consists of two steps. The first step
is to solve the following sub-problem
(L∗k , S∗k) = argminL,S l(L, S,Yk). (10)
The second step is to update the Lagrange multiplier
matrix using the following equation
Yk+1 = Yk + μ (D − Lk − Sk) . (11)
Since a jointly optimal solution for the sub-problem
(10) is not available, a practical and efficient solution is
to employ the alternating optimization algorithm. This
alternating-based method first minimizes l(L, S,Yk) with
respect to L (S is fixed), then it minimizes l(L, S,Yk) with
respect to S (L is fixed). This strategy utilizes the fact that
both min L {l(L, S,Y)} and min S {l(L, S,Y)} have a closed
form solution. In particular, let Sτ :  →  be the
shrinkage operator defined by
Sτ (x) = sgn(x)max(|x| − τ , 0), (12)
where τ ≥ 0 represents the threshold value. This shrink-
age operator is extended to matrices by applying it to their
elements. Then,
S∗ = argminS l(L, S,Y)
= Sλμ−1(D − L + μ−1Y). (13)
To solve for L, let Dτ denotes the singular value thresh-
olding operator given by
Dτ (X) = USτ ()VT , (14)
where X = UVT is the singular value decomposition
(SVD) of X. Then,
L∗ = argminL l(L, S,Y)
= Dμ−1(D − S + μ−1Y). (15)
Though we have a closed-form solution for S∗k and L∗k ,
solving the sub-problem (10) requires computing (13) and
(15) repeatedly until converging to the optimal solution.
This repetition leads to a significant computation burden.
According to [35], this burden can be avoided by updating
Sk and Lk only once. Even though this does not guarantee
the optimal solution of the sub-problem (10), it is suffi-
cient to converge to the optimal solution of the RPCA
problem as proved in [35].
Extracting the differentially abundant bacteria via RPCA
The proposed method for identifying metagenomic
biomarkers is divided into two steps. First, apply RPCA
to decompose the original bacterial abundance level data
into a low-rank matrix representing the non-differential
abundant bacteria and a sparse matrix representing
the differential abundant bacteria. Second, score each
microbe (i.e., feature) by constructing a scoring vector
based on the extracted sparse matrix. The top m bacteria
are selected as biomarkers for the biological process under
study.
Consider the bacterial abundance level matrix D ∈
p×N+ . Each column of D (denoted by di) represents the
abundance levels of the p microbes in one sample. Each
row represents the abundance level of one bacteria in
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all the N samples. Typically, p  N which signifies
a classical high-dimensional small-sample problem. As
mentioned in the Introduction section, it is reasonable to
consider the observed abundance matrix D as being the
sum between a low-rank matrix L and a sparse matrix S.
Potential biomarkers are expected to exhibit abundance
levels that vary between samples belonging to different
groups. Therefore, their abundance levels can be mod-
eled as a sparse perturbation matrix superimposed over
the low-rank matrix representing the abundance levels
of the non-differentiable microbes (i.e., D = L + S).
Consequently, the microbial biomarkers can be detected
according to the sparse matrix S. The bacteria exhibiting
more variation are stronger. The extracted sparse matrix
S can be expressed as
S =
⎡
⎢⎢⎢
⎣
s11 s12 . . . s1n
s21 s22 . . . s2n
...
... . . .
...
sp1 sp2 . . . spn
⎤
⎥⎥⎥
⎦
=[ s1, s2, . . . , sn] . (16)
Corresponding to the original abundance level data
matrix D, each column contains the differential abun-
dance levels of all the microbes in one sample, and each
row of S represents the differential variation of a microbe
in all the N samples. The entries of S can be either
positive or negative reflecting whether the bacteria were
activated or deactivated in response to the biological pro-
cess. Therefore, the absolute values of the entries in S are
needed for the identification of the differentially abundant
bacteria (i.e., biomarkers). The score of the i′th bacteria
is calculated by summing row wise the absolute values of
the i′th row in S. Mathematically, the scoring vector (v) is
obtained by summing the absolute values of the elements
of S, and can be expressed as:
v =
⎡
⎣
N∑
j=1
|s1j|, . . . ,
N∑
j=1
|spj|
⎤
⎦
T
. (17)
Large scores are associated with microbes exhibiting
larger variation between the two states. Therefore, only
the genes with the top r scores are selected as biomarkers.
Nearest centroid classifier (NCC)
A nearest centroid classifier is an instance of distance-
based supervised learning method. The classification pro-
cess using NCC consists of two steps. The first step is to
train the classifier with labeled data (i.e., di) to compute
themean (i.e., centroid) of each class. Themean of the k′th
class (μCk ) is defined by:
μCk =
1
|NCk |
∑
di∈Ck
di, (18)
where |NCk | denotes the number of samples belonging
to k′th class. The second step reduces to assigning a test
sample (z) to the class whose centroid is closer. Mathe-
matically, this is equivalent to the following optimization
problem:
Cˆ(z) = argmin
Ck
dis(μCk , z) (19)
where dis(μCk , z) is a distance measure between the test
sample z and the centroid of the k′th classifier (μCk ).
Results and discussions
This section presents the experimental evaluations on
the two metagenomic studies described in the Material
and Methods section. The performance of our proposed
scheme, RPCA, is compared with the current state-of-
the-art algorithms proposed for identifying microbial
biomarkers. In particular, RPCA is compared with two
statistical-based algorithms namely, MetaStats [28] and
LEFSe [15], and two machine learning-based algorithms.
For the machine learning-based algorithms, an entropy-
based and a binary classification (BC)-based [38] filtering
approach are used.
The five algorithms were evaluated in terms of their
classification and consistency performance according to
the consistency-classification evaluation protocol shown
in Fig. 1. In our experiments, 500 subsamples (i.e., K =
500) were generated by randomly subsampling, without
replacement, the original datasets. Due to the limited
number of samples in metagenomic studies, subsamples
were generated with 80% of the samples in the original
dataset (i.e., r = 0.8). The reported results represent the
average over the 500 experiments.
To reduce the dependency of the results on the clas-
sification criteria, two variants of the nearest centroid
classifiers were used. In the first approach, the l1 norm
was used as a measure of distance, while in the second
approach, the l2 norm was used. In this paper, we refer
to the first classifier as NCC-1 and to the second one
as NCC-2. The consistency of the biomarker detection
algorithms has been measured by the Kuncheva index. In
order to study the impact of the number of selected fea-
tures on the consistency and classification performance,
the five biomarker detection algorithms were assessed at
different sizes of the biomarker sets.
It is worth to mention that there are several implemen-
tations for the RPCA algorithm. In our experiments, we
utilize the Matlab code for the exact ALM provided by the
authors of [37], which is available at ‘http://perception.csl.
illinois.edu/matrix-rank/sample_code.html’.
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Canine inflammatory bowel disease (IBD) dataset
The performance of the five algorithms in terms of their
classification accuracy for varying number of biomark-
ers from the canine IBD dataset is depicted in Fig. 2.
The first row in Fig. 2 presents the results for the NCC-
1 classifier, while the second row presents the results for
the NCC-2 classifier. As the results displayed in Figs.2a
and b illustrate, RPCA outperforms the LEFSe, entropy-
based and BC-based algorithms in terms of accuracy. In
particular, the RPCA algorithm outperforms the LEFSe
and entropy-based algorithms by around 13% and the
BC-based algorithm by approximately 20%. The MetaS-
tats algorithm provides comparable results to RPCAwhen
NCC-1 is used. However, the RPBC algorithm signif-
icantly outperforms the MetaStats performance in the
NCC-2 case. Moreover, RPCA provides a robust result
irrespective of the variation in the applied classification
method and the number of selected biomarkers. This
contrasts the performance of MetaStats.
Our next simulation sought to examine the consistency
performance of the five methods. Figure 3 presents the
KI stability values averaged over all the pairwise compar-
isons (i.e., K(K−1)2 = 124750 comparisons; K = 500). In
addition to the superior consistency performance, RPCA
shows a robust performance irrespective of the number of
selected markers. Detailed consistency analysis when the
size of the selected biomarkers equals 50 is depicted in
Fig. 4 by presenting the histogram of the KI index com-
puted over all pairwise comparisons. As is turns out from
Fig. 4a, the RPCA algorithm shows a high consistent per-
formance. This is revealed form the concentration of the
histogram corresponding to RPCA at high consistency
values. In particular, for almost 80% of the times, RPCA
provides a stability value that is larger than or equal to
90%. On the other hand, LEFSe and MetaStats turn out
to present inconsistent performance. For example, LEFSe
presents KI values less than or equal to 60% for almost half
of the times. The entropy-based and BC-based algorithms
yield a very poor consistency performance.
The top 20 detected biomarkers by the RPCA algorithm
are shown with their scores in Fig. 5. According to [39],
Erysipelotrichaceae is considered to be a major player
in maintaining homeostasis in response to inflammation.
This may explain the selection of two clades (i.e., Eubac-
teriumbiforme and g_Catenibacterium) that belong to
the Erysipelotrichaceae family as possible biomarkers for
IBD. In agreement with previous studies, Collinsella [40]
shows an increase in its abundance, whereas Turicibacter
Fig. 2 Classification performance of the five algorithms over the canine IBD dataset in terms of accuracy, sensitivity and specificity. The first row
represents the results corresponding to the NCC-1 classifier (a accuracy, b sensitivity, c specificity), while the second row represents the NCC-2
classifier results (d accuracy, e sensitivity, f specificity)
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Fig. 3 The average consistency performance measured by KI of the
five biomarker discovery algorithms over the canine IBD dataset
[41] exhibits reduced concentration in IBD subjects. This
may explain selecting species belonging to these clades as
potential biomarker for IBD.
Species belong to several genera, including Blau-
tia (i.e., Blautiaproducta and two unspecified species),
Ruminococcus (i.e., Ruminococcusgnavus), and a num-
ber of taxa within the family of Lachnospiraceae show
decreased abundances in IBD patients [42]. On the other
hand, Lactobacillus and Streptococcus exhibit an increase
in their abundance levels in patients with Crohn’s disease
[42]. Fusobacterium has previously been suggested as a
biomarker for IBD [43].
In order to validate the detected markers by RPCA, an
independent validation experiment has been conducted.
In particular, quantitative PCR (qPCR) assays targeting
thirteen bacterial groups were conducted over fecal DNA
samples taken from 285 healthy dogs and 172 dogs with
chronic enteropathy (CE) [44]. In this experiment, the
final PCR panel (i.e., Faecalibacterium, Turicibacter, E.
coli, Streptococcus, Blautia, and Fusobacterium) includes
five OTUs (i.e., Faecalibacterium, Turicibacter, Strepto-
coccus, Blautia, and Fusobacterium) that are strongly sug-
gested as potential signature for IBD by our RPCA-based
algorithm.
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Fig. 4 Histogram plots of all the 124750 pairwise KIs (i.e., K(K−1)2 = 124750 comparisons; K = 500) generated by the five biomarker discovery
algorithms over the canine IBD dataset. a RPCA. b LEFSe. cMetaStats. d Entropy. e Binary classification
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Fig. 5 Top 20 identified biomarkers by RPCA in relation to the canine
IBD dataset and their RPCA scores. Blue: the selected bacteria exhibit
an increase in their abundance level in the control samples. Red: the
selected bacteria exhibit an increase in their abundance level in the
IBD samples
As shown in the Additional file 1, the RPCA is the only
algorithm that has suggested Faecalibacterium and Blau-
tia as potential biomarker for IBD. In particular, Blautia
has been proposed as a strong driver for IBD by RPCA
and three species from Blautia genera (rank 5, 9, and 18)
were selected in the top 30 markers. Moreover, the Strep-
tococcus has been strongly suggested as strong potential
marker for IBD by RPCA. Specifically, one species of
Streptococcus was ranked second by RPCA. This agrees
with Metastats which suggested two species belonging to
Streptococcus genera (rank 3 and 8), and BC which sug-
gested one Streptococcus species with rank 23 as IBD
marker. On the other hand LEFSe and Entropy algo-
rithms do not include Streptococcus in their suggested
lists of IBD markers. RPCA and LEFSe are the only algo-
rithms that suggested Turicibacter as a signature for IBD.
Fusobacterium was strongly recommended as possible
marker for IBD by RPCA and MetaStats (rank 12 and 5,
respectively) while it is less favored by LEFSe (rank 25).
This independent validation experiment demonstrates the
efficiency of RPCA-based algorithm in identifying mark-
ers with high classification potential.
Fig. 6 Classification performance of the five algorithms over the mouse model of UC dataset in terms of accuracy, sensitivity and specificity. The first
row represents the results corresponding to the NCC-1 classifier (a accuracy, b sensitivity, c specificity), while the second row represents the NCC-2
classifier results (d accuracy, e sensitivity, f specificity)
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Mouse model of ulcerative colitis (UC) dataset
Figure 6 presents the classification performance of the five
algorithms for varying number of biomarkers from the
ulcerative colitis mice model dataset. The first and sec-
ond row represents the classification performance corre-
sponding to the NCC-1 and NCC-2 classifier, respectively.
The results in Fig. 6a and d demonstrate that the RPCA
algorithm outperforms all the four methods in terms of
classification accuracy.Moreover, RPCA exhibits a consis-
tent performance regardless of the classification method
and the number of biomarkers included in the classifier
models. On the other hand, the other four algorithms
exhibit a variation in their accuracy by around 10% when
varying the number of selected markers from 10 to 100.
The average KI values over all the pairwise compar-
isons and their histogram when the number of selected
biomarkers equals 30 are depicted in Figs. 7 and 8, respec-
tively. Figure 7 points out that RPCA exhibits a very high
consistency performance and outperforms all the other
algorithms. In particular, when the number of markers is
larger than 30, RPCA provides an improvement by around
10–15% over the LEFSe, MetaStats and entropy-based
algorithms, and approximately 20% over the BC-based
method. This improvement increases when the number of
markers is less than 30. For example, for a marker set of
size 10, this gain increases to 30 and 20% when RPCA is
compared to MetaStats and LEFSe, respectively.
Fig. 7 The average consistency performance measured by KI of the
five biomarker discovery algorithms over the mouse model of UC
dataset
The distributions of the all pairwise KI for the five
algorithms are depicted in Fig. 8. These histograms pro-
vide a finer view of the consistency performance of the
algorithms. Figure 8a demonstrates that the RPCA algo-
rithm provides a consistent performance as the KI values
exceeds 95% for almost 80% of the times. The other algo-
rithms show much less consistent performance compared
to RPCA. This behavior is clear from the facts that the his-
tograms of these methods are centered at lower values for
KI and the wide spread of KI values.
The top 10 identified biomarkers by the RPCA
algorithm are listed in Fig. 9. RPCA suggests the
enrichment of Oscillibacter, Alistipes, Helicobacter and
Escherichia/Shigella as potential biomarkers for UC. This
agrees with previous studies. For example, the authors
of [45] found that Alistipes presents a very low abun-
dance level in almost all patients diagnosed with UC.
The previous study [12] reported that consistent reduc-
tions of acetate producer clades such as Ruminococ-
caceae, to which Oscillibacter belongs, may negatively
impact the host ability to repair the epithelium and
to regulate inflammation. For Helicobacter, the authors
of [46] reported significant lower rates of Helicobacter
pylori, the most widely known species of Helicobac-
ter genus, in UC patients. Also, the increased levels of
the Escherichia/Shigella has been linked to the intestinal
inflammation [47].
In agreement with the previous studies, RPCA asso-
ciates the reduction in the concentration of Lactobacillus,
Bifidobacterium and Bacteroides to UC. Previous stud-
ies have reported similar results. For example, decreased
concentrations of Lactobacillus and Bifidobacterium in
colonic biopsy specimens and reduced faecal concentra-
tions of lactobacilli and bifidobacteria have been found in
patients with active UC [48, 49]. According to [50], the
UC can be characterized by the decrease in the abundance
levels of Bacteroides. This analysis highlights the agree-
ment of RPCA with the biological findings and suggests
additional taxa as possible biomarkers for UC.
Conclusions
Recent advancements in metagenomic sequencing enable
researchers to investigate the diverse microbial com-
munities with reasonable costs. Despite these advance-
ments, analyzing these massive metagenomic datasets
to derive consistent biological conclusions is a chal-
lenge. Due to the increasing number of metagenomic
studies that associate microbes with several diseases,
identifying potential metagenomic biomarkers in rela-
tion to a specific biological process is crucial for (a)
understanding that process, and (b) developing possible
therapies. Therefore, robust and consistent analytical
techniques that ensure the reproducibility of the results
are essential for clinical applications. Toward this end, we
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Fig. 8 Histogram plots of all the 124750 pairwise KIs (i.e., K(K−1)2 = 124750 comparisons; K = 500) generated by the five biomarker discovery
algorithms over the mouse model of UC dataset. a RPCA. b LEFSe. cMetaStats. d Entropy. e Binary classification
first described an evaluation protocol that assesses the
reproducibility performance of the biomarker detection
algorithm, as shown in Fig. 1. This evaluation protocol
estimates the consistency (i.e., reproducibility) perfor-
mance based on generating different variations of the
original data using random subsampling without replace-
ment. Then, a biomarker detection algorithm is employed
over all the generated subsamples. The pairwise sim-
ilarity between all the marker lists is computed using
a measure of similarity. Second, we proposed a RPCA-
based biomarker detection algorithm that permits the
characterization of specific microbial taxa that are dif-
ferentially expressed between samples belonging to two
different classes.
Comprehensive comparisons with state-of-the-art
biomarker discovery algorithms belonging to the class
of statistical methods and the class of machine learn-
ing approaches were conducted. The obtained results
were evaluated (i) statistically in terms of classification
accuracy and reproducibility performance and (ii) bio-
logically by discussing their biological relevance to the
case under study and their agreement with previous
studies. Experiments were conducted on two realistic
datasets. The first dataset is in relation to healthy dogs
and dogs diagnosed with IBD. The second dataset is a
mouse model of ulcerative colitis. Experiments show
that the RPCA algorithm effectively detects microbial
biomarkers in both datasets. In particular, the detected
biomarkers by the RPCA algorithm exhibit high accuracy
in discriminating the metagenomic samples belonging to
different phenotypes. More importantly, RPCA shows a
high reproducibility performance when compared with
the other algorithms. These findings demonstrate that (i)
the concept of modeling the abundance level matrix as
the sum of a low-rank matrix representing the irrelevant
bacteria and a sparse matrix containing the abundances
of informative bacteria, (ii) the use of RPCA to recover
this sparse matrix, and (iii) the inherent multivariate
nature of RPCA that handles the complex microbial inter-
actions, were successful in finding potential metagenomic
biomarkers with high reproducibility and discriminative
power.
The proposed framework for assessing the reproducibil-
ity provides a simple yet effective guidance for the design
and evaluation of biomarker discovery algorithms. Addi-
tionally, the proposed RPCA-based biomarker detection
algorithm contributes to the identification of microbial
biomarkers that might explain the differences between
bacterial communities under different conditions. In
addition to outperforming the current state-of-the-art
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Fig. 9 Top 10 identified biomarkers by RPCA in relation to the mouse
model of ulcerative colitis dataset and their RPCA scores. Blue: the
selected bacteria exhibit an increase in their abundance level in
control samples. Red: the selected bacteria exhibit an increase in their
abundance level in UC samples
metagenomic biomarker detection algorithms, the pre-
sented results reveal that RPCA is a robust and reliable
tool for identifying such biomarkers.
Reviewers’ comments
Reviewer’s report 1: Reviewer #1: Masanori Arita, The
University of Tokyo, Japan
The manuscript applies the SPCA to the metagenomic
data. As far as I know, this is the first application to
metagenomics although the approach has been used
for other bioinformatics (gene expression analysis). The
introduction part is nicely written and the comparison
with other approaches is fair. Reviewer recommendations
to authors:
1. The key question here concerns the benefit of using
SPCA and discussion. Finding the same taxa as those
reported previously was a good indication. But were
the results always equal? What were the differences?
Such detailed analysis are necessary in the discussion
because the current manuscript only briefly
compares the different approaches.
Author’s response: The reviewer has pointed important
comments. The response for these comments is divided
into three parts. The first part explains the importance
of the comparisons with other approaches. The second
part considers the benefits of our proposed algorithm.
The third part addresses the discussion of the similarities
and differences between the detected markers by different
approaches.
First part: A major bottleneck for the evaluation of
biomarker discovery algorithms is the lack of “ground
truth” (i.e., the true biomarkers) to objectively evaluate the
performance of biomarker detection algorithms. To over-
come this problem, researchers usually resort to statistical
and biological evaluation of detected markers. Regarding
the statistical assessment, the evaluation criteria and com-
parisons have to be suitably designed in order to mimic the
knowledge of true markers. In particular, the evaluation
metrics need to capture the features of the true biomark-
ers. True biomarkers are characterized by two properties.
The first property is that true markers enable to distin-
guish samples belonging to different phenotypes. In general,
this feature is measured via the classification performance
of a classifier model built using only the selected biomark-
ers. The second feature is that true signatures tend to be
robust against small variations in the training set. This
feature can be assessed through the empirical estimation
of the stability of a biomarker detection algorithm. There-
fore, our paper includes extensive comparisons in order
to provide a fairer and more accurate evaluation of the
competing methods, and to reflect our confidence about
the biological conclusions. For example, if an algorithm
exhibits an inconsistent performance and/or poor classifi-
cation performance, this puts its biological findings under
question.
Second part: Based on the conducted comprehensive sim-
ulation experiments. The RPCA-based biomarker detec-
tion algorithm provides a high reproducibility performance
with quite high discriminative accuracy irrespective of
the complexity of the dataset or the number of selected
biomarkers. In addition, the convex formulation of RPCA
provides a natural way to incorporate prior knowledge
about the biological process under study, which may lead
to more accurate results.
Third part: The selected markers by the five competing
algorithms over the two datasets have been included [see
the Additional files 1 and 2]. Additionally, we included
more details in the manuscript about the agreements and
disagreements between the identified markers by the five
algorithms over the two datasets. Please check the response
for comment number 3 below for discussion regarding the
canine with IBD dataset. Regarding themousemodel of UC
dataset, the following paragraph was added:
‘The Additional file 2, which lists the top 10 detected
markers by the five algorithms, shows that 8 out of the
10 identified markers by RPCA and LEFSe are in com-
mon. Instead of Desulfovibrio and Butyricicoccus which
are identified by LEFSe, RPCA suggested Bacteroides and
Lactobacillus as potential markers for UC. RPCA shows
less agreement with MetaStats in which only 3 signatures
are in common between them. Specifically, RPCA and
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MetaStats agrees on Bifidobacterium, Streptococcus, and
Escherichia/Shigella as possible markers for UC. On the
other hand, RPCA does not share any of its detected mark-
ers neither with the Entropy-based method nor with th BC
algorithm.’
2. In a standard viewpoint, the matrix S (perturbation)
may contain noise. So the discussion to distinguish
noise from the IBD key is also necessary.
Author’s response: The optimization problem formu-
lation for extracting the low-rank and sparse matrices
provides a natural robustness against Gaussain noise. In
particular, the third term in the optimization problem (9),
which measures the error between the bacterial abundance
data and the extracted low-rank and sparse matrices in
the Euclidian norm, reflects the maximum likelihood esti-
mation of the parameters (i.e., L and S) in the presence of
Gaussian noise. Therefore, we expect that the RPCA algo-
rithm will exhibit robust performance against Gaussian
noise. However, it is known that the Euclidian distance is
sensitive to nonGaussian noise and outliers. In such cases,
the raw bacterial abundance data may be preprocessed to
mitigate the impact of such noises by using special filters
such as median filters.
3. This paper may be good as a methodology paper, but
for a research, application of the MatLab code is not
enough. Please enhance the biology part of this
presentation more in details.
Author’s response: We thank the reviewer for this sug-
gestion. In response for this comment, the following com-
ments have been added to the manuscript: ‘In order to
validate the detected markers by RPCA, an independent
validation experiment has been conducted. In particular,
quantitative PCR (qPCR) assays targeting thirteen bac-
terial groups were conducted over fecal DNA samples
taken from 285 healthy dogs and 172 dogs with chronic
enteropathy (CE) [44]. In this experiment, the final PCR
panel (i.e., Faecalibacterium, Turicibacter, E. coli, Strep-
tococcus, Blautia, and Fusobacterium) includes five OTUs
(i.e., Faecalibacterium, Turicibacter, Streptococcus, Blau-
tia, and Fusobacterium) that are strongly suggested as
potential signature for IBD by our RPCA-based algorithm.
As shown in the Additional file 1, the RPCA is the only
algorithm that suggested Faecalibacterium and Blautia as
potential biomarker for IBD. In particular, Blautia was
proposed as a strong driver for IBD by RPCA and three
species from Blautia genera (rank 5, 9, and 18) were
selected in the top 30 markers. Moreover, the Streptococ-
cus was strongly suggested as strong potential marker for
IBD by RPCA. Specifically, one species of Streptococcus
was ranked second by RPCA. This agrees with Metas-
tats which suggested two species belonging to Streptococcus
genera (rank 3 and 8), and BC which suggested one Strep-
tococcus species with rank 23 as IBD marker. On the other
hand LEFSe and Entropy algorithms do not include Strep-
tococcus in their suggested lists of IBD markers. RPCA and
LEFSe are the only algorithms that suggested Turicibac-
ter as a signature for IBD. Fusobacterium was strongly
recommended as possible marker for IBD by RPCA and
MetaStats (rank 12 and 5, respectively) while it is less
favored by LEFSe (rank 25). This independent validation
experiment demonstrates the efficiency of RPCA-based
algorithm in identifying markers with high classification
potential.’
4. Instead of writing the details of the alternating based
method, please inform the Matlab code and library
for biology users.
Author’s response: Done. A link for the Matlab code
has been provided in the manuscript: “It is worth to men-
tion that there are several implementations for the RPCA
algorithm. In our experiments, we utilize the Matlab code
for the exact ALM provided by the authors of [34], which
is available at http://perception.csl.illinois.edu/matrix-
rank/sample_code.html.” The details of the alternating
based method was provided for the sake of completeness.
5. Formula (5) was not properly printed in my printer
setting. It is not recommended to separate formulas
by a comma here because it looks like "FP’". Maybe
inserting some space (LaTeX backslash?) is better.
Author’s response: The authors believe that separating
the three equations by comma is appropriate here.
6. Bacterial taxonomy is not very familiar to most
readers. Genus may be not enough. For example,
Blautia and Ruminococcus are very close.
Lactobacillus is a very large clade. Are there more
general trends?
Author’s response: For the mouse model of UC dataset,
we have only the bacterial abundance data analyzed at the
genus level. We do not have the original sequences to ana-
lyze the data at lower phylogenetic depth (i.e., at species
level). For the canine with IBD dataset, the experiments
have been conducted at the species level.
Quality of written English
Acceptable
Reviewer’s report 1: Reviewer #2: Zoltan Gaspari, Pazmany
University, Budapest
The manuscript describes the application of the RPCA
method for biomarker detection inmetagenomic samples.
The advantages of the method seem convincing and the
comparative nature of the study offers important insights
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for those working in the field. Reviewer recommendations
to authors:
1. The diversity of the samples might be one of the
reason why the histograms and the performance of
some methods differ substantially. Can the authors
offer a measure for this?
Author’s response: The reviewer has made an interest-
ing comment. In fact, this is the main motivation for our
work. In reality, metagenomic datasets exhibit some kind
of diversity or variation among them. The platforms used
to implement the experiments, the sample size, and the dif-
ferences between subjects participating in the experiments
are few examples of possible reasons for this variation.
Therefore, it is important to develop an algorithm that
provides a robust performance irrespective of the natural
diversity of the samples. Indeed, measuring the diversity of
the samples may provide further insights about the diver-
sity of the bacterial compositions in the samples. In the
field of ecology, researchers commonly use three measures
of the biodiversity (species diversity) of the samples. These
measures are the alpha diversity (α−diversity), beta diver-
sity (β−diversity), and gamma diversity (γ−diversity).
However, measuring such a diversity is out of the
scope of this paper. This is because all algorithms were
tested using the same samples (under the same sample
diversity).
2. Changes in the numbers of an abundant microbe
relative to a rare one might be of different
meaning/importance, is this factor relevant in the
analysis?
Author’s response:We thank the reviewer for raising this
important point. Indeed the variation in the abundance
levels might have different meanings. For some methods,
this issue may lead to a serious bias problem in the sense
that variables (i.e., microbes) with more abundance levels
may be preferred over those with less abundance levels. For
example, the Random Forest (RF) model, which is a very
popular classifier and variable ranking technique is biased
in favor of features with larger values [51]. On the other
hand, our algorithm does rely on the abundance range of
the variables. In fact, our RPCA-based algorithm does not
require any prior knowledge about the microbial abun-
dance profiles. Moreover, the ranks assigned by the RPCA
are not correlated with the absolute and/or fold change
variation in the mean values of the variables between
healthy and diseased samples as it is transparent from the
supplementary material added to the manuscript [see the
Additional files 1 and 2].
3. Kindly consider this essay about the 1:10 ration of
human vs. bacterial cells: http://www.nature.com/
news/scientists-bust-myth-that-our-bodies-have-
more-bacteria-than-human-cells-1.19136.
Author’s response: Thanks. We have considered your
suggestion in the manuscript. In particular, the following
statement has been added to the manuscript:‘Some studies
have reported that the microbes outnumber the human’s
cells by a ratio of 10:1 [2], while others limits this ratio to
1.3:1 [3].’
4. Please explain all variables in the equations
(including tau, p, mu etc.)
Author’s response: Sorry, we didn’t make it clear.
Description of the variables that were not defined has been
added.
• μ stands for the single regularization parameter
associated with the ALM formulation (after Eq. (8)).
• τ ≥ 0 represents the threshold value (after Eq. (12))
5. Is a division missing from Eq. 18?
Author’s response:Modified. Thanks.
6. LEfSe is written with small f" on page 4 and with
capital everywhere else
Author’s response: Done. Thanks.
Quality of written English
Acceptable.
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